Vivos Therapeutics (VVOS) Closes $7.5M ATM
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Nasdaq, S&P end lower as tech stocks fall
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- JPMorgan raises S&P 500 target to 7,800, says earnings revision ’unprecedented’
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- UBS Reiterates Buy Rating on Snowflake Inc. (SNOW)
Vivos Therapeutics Closes $7.5 Million At-The-Market Private Equity-Backed Investment and Launches Strategic Marketing and Distribution Alliance
June 12, 2024 7:30 AM EDTAlliance with Sleep Treatment Provider in Colorado Marks Critical Pivot in Vivos Marketing and Distribution Model Aimed at Enhancing Revenue Streams and Potential Profit
Private Placement Investment Sponsored by Seneca Partners, Who Will Also Provide General Management Advisory Services to Fuel Growth Prospects
LITTLETON, Colo., June 12, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (Vivos or the Company) (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep-related breathing disorders (including all... More
